AMI Asset Management
VRDN icon

AMI Asset Management’s Viridian Therapeutics VRDN Stock Holding History

AMI Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.03M Buy
+49,959
New +$1.07M 0.06% 51

Other funds holding VRDN

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Owl Creek Wealth Partners
Owl Creek Wealth Partners Denver, Colorado $355M AUM
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

AMI Asset Management's VRDN Position: Q3 2026 in Review

AMI Asset Management opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 49,959 shares worth $1.03M. The stake represents 0.06% of the portfolio and ranks #51 among its holdings.

9 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • AMI Asset Management held 49,959 shares of Viridian Therapeutics worth $1.03M as of Q3 2026.
  • Viridian Therapeutics was a new AMI Asset Management position in Q3 2026.
  • Viridian Therapeutics made up 0.06% of AMI Asset Management's portfolio in Q3 2026, its #51 holding.
  • 9 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on AMI Asset Management's 13F filing for Q3 2026, filed 20 Oct 2026.